PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jan 23, 2020
- Study meets primary endpoint in patients living with type 1 SMA - - To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial - - Risdiplam PDUFA expected May 24, 2020 - SOUTH
Additional Formats
Jan 13, 2020
- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's new redox platform to begin in 2020 - - ~ $306 million preliminary unaudited 2019 total revenue - - 2020 Duchenne franchise revenue guidance of $320-340 million - SOUTH PLAINFIELD, N.J. , Jan.
Additional Formats
Jan 06, 2020
SOUTH PLAINFIELD, N.J. , Jan. 6, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 th at 8:30 a.m. PST .
Additional Formats
Dec 13, 2019
SOUTH PLAINFIELD, N.J. , Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees.
Additional Formats
Nov 29, 2019
SOUTH PLAINFIELD, N.J. , Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of its common stock to 36 new employees.
Additional Formats
Nov 25, 2019
- PDUFA date set for May 24, 2020- - NDA filing is based on data in a broad SMA population of Type 1, 2 and 3 patients- - FDA filing triggers $15M milestone payment to PTC from Roche- SOUTH PLAINFIELD, N.J. , Nov. 25, 2019 /PRNewswire/ --   PTC Therapeutics, Inc.
Additional Formats
Nov 19, 2019
SOUTH PLAINFIELD, N.J. , Nov. 19, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will participate in a panel discussion titled, "Gene Therapy with Base Business – Extracting Value," at the 2 nd Annual Evercore ISI HealthCONx Conference on Tuesday,
Additional Formats
Nov 18, 2019
- AADC deficiency patients are often misdiagnosed as having other neurological conditions such as cerebral palsy - SOUTH PLAINFIELD, N.J. , Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid
Additional Formats
Nov 11, 2019
- Study meets primary endpoint for patients living with type 2/3 SMA - - Risdiplam has been well tolerated and there have been no drug-related safety findings leading to withdrawal from the study - SOUTH PLAINFIELD, N.J. , Nov. 11, 2019 /PRNewswire/ --   PTC Therapeutics, Inc.
Additional Formats
Oct 31, 2019
SOUTH PLAINFIELD, N.J. , Oct. 31, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on October 25, 2019 it approved non-statutory stock options to purchase an aggregate of 339,875 shares of its common stock to 27 new employees.
Additional Formats